Lifarizine

Drug Profile

Lifarizine

Alternative Names: RS 87476

Latest Information Update: 25 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Roche Palo Alto
  • Class Anti-ischaemics; Imidazoles; Nootropics; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 24 Jan 2017 Discontinued - Phase-II for Stroke in USA (unspecified route)
  • 12 Jan 2001 Profile reviewed but no significant changes made
  • 26 Feb 1997 Suspended-II for Stroke in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top